Skip to main content
Premium Trial:

Request an Annual Quote

Ben Bulkley, Bernd Brust, John Radak, Kelli Richard

Ben Bulkley and Invitrogen have mutually agreed for his departure from the company, Invitrogen said in a document filed with the US Securities and Exchange Commission this week. Bulkley is senior vice president of commercial operations. His departure date is Jan. 31. Bernd Brust, senior vice president of global sales, will replace him.
The company also announced the resignation of John Radak as VP for finance and principal accounting officer, effective Jan. 31. He will be replaced by Kelli Richard, who has been corporate controller at Invitrogen since August 2005. Richard will receive a base salary of $225,000 in her new position.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.